1. ALLA AKTIER
  2. NYHETER
  3. MENDUS

Mendus

Nyheter Mendus Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Mendus to participate in investor and industry conferences in February

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:

BIO Capital 2025
Amsterdam, The Netherlands, February 5 – 6, 2025
Mendus CEO Erik Manting will attend

Cell & Gene Therapy Manufacturing Summit 2025
Basel, Switzerland, February 12 – 14, 2025
Mendus CTO Leopold Bertea will hold a presentation about establishing large-scale manufacturing for Mendus’ lead program vididencel and participate in a panel discussion about challenges and solutions in the manufacturing and supply chain of cell therapy products
For more information, please see Cell & Gene Therapy Manufacturing Summit 2025

Biologics Manufacturing Germany
München, Germany, February 18 – 19, 2025
Mendus CTO Leopold Bertea will hold a presentation about establishing large-scale manufacturing for Mendus’ lead program vididencel and participate in a panel discussion about evolving collaboration models between biopharmaceutical companies and manufacturing organizations
For more information, please see Biologics Manufacturing Germany

For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/

Attachments
Mendus to participate in investor and industry conferences in February

Datum 2025-02-04, kl 08:00
Källa MFN
Bifogade filer
Mendus to participate in investor and industry conferences in February